Compare Mercadolibre Inc (MELI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Novo Nordisk A/S — how do they compare? Mercadolibre Inc trades at $1,814 (market cap $92.90B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2.4× Mercadolibre Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | NVO | |
|---|---|---|
Market Cap | $92.90B | $220.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $71.70 |
52-Week Low | $1.55K | $35.29 |
Enterprise Value | $99.79B | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,822.65, up 0.48% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with key resistance near $1,833, while recent earnings have missed expectations for three consecutive quarters. Revenue growth remains robust, reaching $28.89 billion in 2025, though net income margins have moderated. Analyst sentiment is strongly positive with a $2,220 consensus price target, but institutional selling and an ongoing legal investigation present near-term headwinds.
The outlook for MELI balances strong long-term growth potential in Latin American e-commerce and fintech against near-term margin pressure and execution risks. Investment appeal hinges on the company's ability to translate top-line expansion into sustained profitability, while key risks include competitive intensity, credit quality concerns, and macroeconomic volatility in core markets.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
